Soon, individuals with celiac disease in southern Spain will begin receiving regular allotments of bread. Rather than misguided charity, this will be a clinical trial of a new type of dough made from genetically modified (GM) wheat. The wheat has been altered to be low in gliadins—the portion of gluten proteins that are toxic to people with celiac disease. If successful, the trial could bolster growing research efforts to engineer wheat to be compatible with the immune systems of the ~1% of the global population with celiac disease and the much larger number of people with gluten allergies.
Low-gluten wheat could also open a new front in the battle for GM food acceptability in Europe. If Europeans are ever going to accept a GM food, celiac-safe wheat may be a good candidate. European consumers accounted for over 1.1 ($1.21) billion of nearly 1.9 billion worldwide gluten-free food market, according to market research firm Euromonitor International. Global gluten-free bakery sales are expected to grow at >7% annually, the firm predicts. But because this and other efforts to modify wheat involve inserting genetic elements to silence genes, they are subject to a European regulatory process closely tied to anti-GM politics. And even if such legal barriers to marketing are overcome, marketing such a wheat would require not just farmers, but millers, bakers and consumers to be persuaded that it is worthwhile. Continue reading